Showing results (471-480 of 1,393) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|January 27, 2022
Clinical Utility of Genomic Testing in Cancer CareDaryl Pritchard, Clifford Goodman, Lincoln D Nadauld
JCO Precision Oncology|September 27, 2021
Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University ExperienceMichelle F Green, Jonathan L Bell, Christopher B Hubbard, et al.
JCO Precision Oncology|September 27, 2021
Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous CarcinomaM Herman Chui, Jason C Chang, Yanming Zhang, et al.
JCO Precision Oncology|February 9, 2022
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical PhenotypeApurva Jain, Mitesh J Borad, Robin Kate Kelley, et al.
JCO Precision Oncology|February 9, 2022
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase InhibitorJonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
JCO Precision Oncology|February 9, 2022
Multi-Institutional, Prospective Clinical Utility Study Evaluating the Impact of the 92-Gene Assay (CancerTYPE ID) on Final Diagnosis and Treatment Planning in Patients With Metastatic Cancer With an Unknown or Unclear DiagnosisSachdev P Thomas, Lauren E Jacobson, Anthony R Victorio, et al.
JCO Precision Oncology|February 9, 2022
Fundamental Concepts in the Application of Plasma Genotyping (Liquid Biopsy) to EGFR Mutation Detection in Non-Small-Cell Lung CancerAdrian G Sacher
JCO Precision Oncology|February 9, 2022
ERBB3-Activating Mutations in Small Bowel AdenocarcinomasLuc Cabel, Thomas Aparicio, Ivan Bieche, et al.
JCO Precision Oncology|February 9, 2022
Elevated Levels of BRAF Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic MelanomaWilliam Lu, Luciana Burton, James Larkin, et al.
JCO Precision Oncology|February 9, 2022
BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF InhibitionTania Moujaber, Dariush Etemadmoghadam, Catherine J Kennedy, et al.
Pageof 140